State of New Jersey Common Pension Fund D reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,961 shares of the biotechnology company’s stock after selling 926 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.06% of United Therapeutics worth $5,864,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also added to or reduced their stakes in the company. Massmutual Trust Co. FSB ADV grew its holdings in United Therapeutics by 61.4% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 163 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 62 shares in the last quarter. Atlas Capital Advisors LLC purchased a new stake in United Therapeutics during the 4th quarter valued at approximately $51,000. Northwestern Mutual Wealth Management Co. grew its holdings in United Therapeutics by 49.6% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 65 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in United Therapeutics during the 2nd quarter valued at approximately $48,000. Finally, Hazlett Burt & Watson Inc. grew its holdings in United Therapeutics by 24.0% during the 2nd quarter. Hazlett Burt & Watson Inc. now owns 248 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 48 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
United Therapeutics Stock Up 1.8 %
Shares of UTHR opened at $216.25 on Tuesday. The company has a market cap of $10.16 billion, a PE ratio of 11.91 and a beta of 0.52. The business has a fifty day moving average of $225.00 and a 200 day moving average of $227.57. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $261.54. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.09.
Insider Buying and Selling
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Wedbush reiterated an “outperform” rating and set a $308.00 target price (up from $307.00) on shares of United Therapeutics in a research report on Thursday, November 2nd. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 1st. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and increased their target price for the company from $213.00 to $215.00 in a research report on Monday. Morgan Stanley lowered their target price on United Therapeutics from $318.00 to $314.00 and set an “overweight” rating for the company in a research report on Thursday, November 2nd. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.80.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
- Five stocks we like better than United Therapeutics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Salesforce and MongoDB: 2 must-own tech stocks
- With Risk Tolerance, One Size Does Not Fit All
- Udemy stock got boosted by analysts, massive growth at discounts
- What is the NASDAQ Stock Exchange?
- 3 attractive stocks that insiders are buying
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.